Humira Continues to Threaten Remicade’s Market-Leading Status in the Treatment of Crohn’s Disease

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the treatment of Crohn’s disease, Janssen Biotech’s Remicade faces stiff competition from Abbott’s Humira. According to Treatment Algorithms in Crohn’s Disease, the two agents garner similar patient share as first-line treatments for newly diagnosed Crohn’s disease patients.

Analysis of patient-level claims data from recently treated patients reveals that Remicade maintained a slightly higher patient share over Humira throughout 2010, and more Crohn’s disease patients switched to Humira from Remicade than vice versa, suggesting that Remicade tends to be used before Humira in the treatment algorithm.

“While Remicade remains the leading biologic for the treatment of Crohn’s disease, Humira may accrue a greater number of patients over time,” said Decision Resources Analyst Bingnan Kang, Ph.D. “When looking at progression rates of newly diagnosed patients, a much smaller percentage of patients using Humira in the first line progress to a second-line treatment within a year of diagnosis compared with Remicade. Thought leaders we’ve interviewed indicate that Remicade’s efficacy diminishes over time and patients must switch to other therapies, which presents an opportunity for Humira.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms Insight series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms Insight series provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.